🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yingmiao Liu

Duke Medical Center

ORCID: 0000-0003-3516-5844

Also affiliated with Duke University Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.694Author DataRank

Indexed papers

5in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2386
Top 29%
0.694DataRank
Top 29%11 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)”.

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2386
Top 29%
0.694DataRank
Top 29%11 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)

The Oncologist(2021)10.1002/onco.13777
N/A
0.360DataRank · unranked
10 citations

Yousef Zakharia, Sumanta Pal, Judit Kocsis, Russell Pachynski, Alexandr Poprach +16 more

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00794-3
N/A
0.208DataRank · unranked
3 citations

Yingmiao Liu, Qian Yang, Bin Luo, Mark D. Starr, John C. Brady +7 more

Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers

Communications Biology(2022)10.1038/s42003-022-03495-6
N/A
0DataRank · unranked
18 citations

Shrikant Pradhan, Roohi Chaudhary, Eduardo Listik, Liz Quintero-Macías, Alex Seok Choi +10 more

Data from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)

(2023)10.1158/1078-0432.c.6531153
Top 100%
0DataRank
Top 100%0 citations

Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey +13 more

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0056
N/A
0DataRank · unranked
224 citations

Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu +13 more

Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

(2023)10.1158/1078-0432.c.6531354.v1
Top 100%
0DataRank
Top 100%0 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Common variation in a long non-coding RNA gene modulates variation of circulating TGF- β 2 levels in metastatic colorectal cancer patients (Alliance)

medRxiv(2023)10.1101/2023.12.04.23298815
N/A
0DataRank · unranked
0 citations

Alexander B. Sibley, Yingmiao Liu, Donna Niedzwiecki, Susan Halabi, Layne Rogers +10 more

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

BMC Genomics(2024)10.1186/s12864-024-10354-7
N/A
0DataRank · unranked
1 citations

Alexander B. Sibley, Yingmiao Liu, Donna Niedzwiecki, Susan Halabi, Layne Rogers +10 more

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

UNC Libraries(2024)10.17615/m9fj-sb76
N/A
0DataRank · unranked
0 citations

Alan P. Venook, William Kevin Kelly, Andrew B. Nixon, Mark J. Ratain, Howard L. McLeod +10 more

Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

(2023)10.1158/1078-0432.c.6531354
Top 100%
0DataRank
Top 100%0 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-0226
N/A
0DataRank · unranked
57 citations

Kirsten B. Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu +16 more

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2389
N/A
0DataRank · unranked
20 citations

Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey +13 more